HomeCompareRDFEF vs ABBV

RDFEF vs ABBV: Dividend Comparison 2026

RDFEF yields 493.83% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RDFEF wins by $55783.16M in total portfolio value
10 years
RDFEF
RDFEF
● Live price
493.83%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55783.26M
Annual income
$39,892,256,504.25
Full RDFEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RDFEF vs ABBV

📍 RDFEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRDFEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RDFEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RDFEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RDFEF
Annual income on $10K today (after 15% tax)
$41,975.31/yr
After 10yr DRIP, annual income (after tax)
$33,908,418,028.61/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RDFEF beats the other by $33,908,396,972.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RDFEF + ABBV for your $10,000?

RDFEF: 50%ABBV: 50%
100% ABBV50/50100% RDFEF
Portfolio after 10yr
$27891.68M
Annual income
$19,946,140,638.01/yr
Blended yield
71.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RDFEF
No analyst data
Altman Z
-0.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RDFEF buys
0
ABBV buys
0
No recent congressional trades found for RDFEF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRDFEFABBV
Forward yield493.83%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$55783.26M$102.3K
Annual income after 10y$39,892,256,504.25$24,771.77
Total dividends collected$54397.91M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RDFEF vs ABBV ($10,000, DRIP)

YearRDFEF PortfolioRDFEF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$60,083$49,382.72$11,550$430.00+$48.5KRDFEF
2$341,583$277,294.18$13,472$627.96+$328.1KRDFEF
3$1,838,834$1,473,340.96$15,906$926.08+$1.82MRDFEF
4$9,380,079$7,412,526.65$19,071$1,382.55+$9.36MRDFEF
5$45,375,044$35,338,359.20$23,302$2,095.81+$45.35MRDFEF
6$208,313,171$159,761,873.86$29,150$3,237.93+$208.28MRDFEF
7$908,366,016$685,470,922.29$37,536$5,121.41+$908.33MRDFEF
8$3,765,456,336$2,793,504,699.72$50,079$8,338.38+$3765.41MRDFEF
9$14,851,408,011$10,822,369,731.23$69,753$14,065.80+$14851.34MRDFEF
10$55,783,263,076$39,892,256,504.25$102,337$24,771.77+$55783.16MRDFEF

RDFEF vs ABBV: Complete Analysis 2026

RDFEFStock

Brookside Energy Limited, together with its subsidiaries, engages in the exploration, production, and appraisal of oil and gas projects. It develops oil and gas assets in the Anadarko Basin in Oklahoma, the United States. The company is also involved in the leasing and development of acreage opportunities. As of December 31, 2021, it owned an area of 3275 working interest leasehold acres in west-central Oklahoma. The company was formerly known as Red Fork Energy Limited and changed its name to Brookside Energy Limited in June 2015. Brookside Energy Limited was incorporated in 2004 and is headquartered in Subiaco, Australia.

Full RDFEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RDFEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RDFEF vs SCHDRDFEF vs JEPIRDFEF vs ORDFEF vs KORDFEF vs MAINRDFEF vs JNJRDFEF vs MRKRDFEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.